BrainsWay Ltd.

BrainsWay Expands U.S. Insurance Coverage for Deep TMS™ Treatment of OCD to Over 118 Million Lives

BrainsWay expanded U.S. insurance coverage for Deep TMS treatment of OCD, bringing covered lives to more than 118 million. The company highlighted its position as the first to receive FDA clearance for a non-invasive brain stimulation OCD treatment and the only TMS company with published randomized, placebo-controlled pivotal data for the indication. The announcement follows recent coverage expansion for the accelerated SWIFT protocol in major depressive disorder, reinforcing a broader payer-adoption trend, though no financial impact was quantified.

•6d ago

BrainsWay Announces Strategic Collaboration with Inland Psychiatry Medical Group

BrainsWay announced a strategic collaboration with Inland Psychiatric Medical Group, a behavioral health provider serving Southern California, including a multisystem order of Deep TMS systems for IPMG clinics. The partnership also includes plans to explore scientific, clinical, and research projects in interventional psychiatry. No financial terms were disclosed; the deal is a modest commercial win supporting BrainsWay's U.S. installation growth strategy.

•13d ago

BrainsWay Reports Rise in Favorable Accelerated Deep TMS™ Coverage to Over 70 Million Covered Lives

BrainsWay announced expanded U.S. insurance coverage for its SWIFT Accelerated Deep TMS protocol, with more than 70 million covered lives now having access under favorable medical policies. CEO Hadar Levy attributed the momentum to a growing clinical evidence base supporting Deep TMS for major depressive disorder and obsessive-compulsive disorder. Reimbursement expansion is a key commercial driver for TMS adoption, but the release contains no financial figures or quantified revenue impact.

•19d ago

BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer’s Disease Treated with Deep TMS™

BrainsWay announced the peer-reviewed publication of pilot study results evaluating its Deep TMS technology in 12 patients with co-occurring major depressive disorder and early-stage Alzheimer's disease, published in the Journal of Geriatric Psychiatry and Neurology. The study reported an 83.3% response rate and a 50% remission rate in depressive symptoms following 36 Deep TMS sessions using the H1 and H7 Coils, alongside QEEG changes suggesting reduced cortical slowing and improved brain connectivity. Management framed the results as validating the platform's potential in complex neuropsychiatric conditions, while noting Deep TMS is not FDA-cleared for Alzheimer's disease and that additional controlled research is required.

•1mo ago

BrainsWay Deep TMS™ Study Shows 70% Reduction in Patients Experiencing Suicidal Ideation

BrainsWay published new peer-reviewed data in the Journal of Affective Disorders demonstrating a 70% relative reduction in suicidal ideation among Major Depressive Disorder patients treated with Deep TMS. The secondary analysis of 89 patients showed the prevalence of suicidal ideation dropped from 22.5% at baseline to 6.7% after six weeks of treatment. Results were consistent across both the SWIFT accelerated protocol and standard once-daily treatment, with median improvement times of 10 and 13 days, respectively.

•2mo ago

BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights

BrainsWay delivered a strong Q2 2026 with revenue increasing 35% year-over-year to $17.1 million and Adjusted EBITDA more than doubling to $3.5 million. The company raised its full-year 2026 guidance, now expecting revenue of $68 million to $70 million and Adjusted EBITDA of $13 million to $14 million, bolstered by record system shipments. Remaining performance obligations grew 30% to $80.4 million, and the company generated $6.3 million in cash flow from operations, highlighting strong commercial execution and backlog visibility.

•2mo ago

BrainsWay Announces Strategic Investment in Radial Health, Inc.

BrainsWay made a $3 million strategic minority equity investment in Radial Health, Inc., participating in the company's Series A financing round to support its network of Brain Medicine clinics. The investment aligns with BrainsWay's strategy to secure positions in high-performing mental health provider networks, thereby expanding access to its Deep TMS therapies. Radial intends to use the financing to expand its clinical footprint, strengthen its AI-guided platform, and explore M&A opportunities.

•3mo ago

BrainsWay Announces Minority-Stake Investment in Sound Minds Behavioral

BrainsWay invested $500,000 for a minority stake in Sound Minds Behavioral, a growth-oriented outpatient behavioral health platform in the Mid-Atlantic. The investment is structured as a preferred, annually compounding security, aimed at expanding patient access to BrainsWay's Deep TMS technology. CEO Hadar Levy noted that the minority stake approach facilitates partner expansion while allowing BrainsWay to focus on scientific advancement.

•3mo ago

BrainsWay Presents Positive Data from Largest Real-World Study of Deep TMS™ in Patients with Comorbid PTSD and Major Depressive Disorder

BrainsWay presented positive real-world data from a 462-patient study showing an 83.5% response rate in PTSD symptoms for comorbid patients treated with Deep TMS. The data also indicated strong efficacy for depression, with a 66.6% response rate and a 27.3% remission rate among the study participants. The company clarified that Deep TMS is not currently FDA-cleared for PTSD and that the findings remain subject to peer review.

•4mo ago

BrainsWay Reports Favorable Coverage for Accelerated Deep TMS™ Rises to Over 57 Million Covered Lives

BrainsWay announced a significant expansion in reimbursement coverage for its SWIFT Accelerated Deep TMS protocol, bringing total covered lives to over 57 million. The update includes a new policy for 2 million members in South Carolina, with eight major payers and the US Department of Veterans Affairs now supporting the treatment for major depressive disorder and obsessive-compulsive disorder. CEO Hadar Levy noted the milestone reflects accelerating adoption and growing clinical evidence supporting the efficacy of Deep TMS therapies.

•4mo ago

BrainsWay Presents First SWIFT™ Accelerated Deep TMS 12-Month Durability Data at Clinical TMS Society Annual Meeting

BrainsWay presented 12-month durability data for its FDA-cleared SWIFT™ accelerated Deep TMS protocol at the 14th Annual Clinical TMS Society Meeting. The prospective study showed that over 80% of patients remained in remission at 12 months, with severe functional impairment dropping from 85% at baseline to 0%. Less than 25% of patients required a change in medication or additional TMS courses during the year, validating the long-term efficacy of the accelerated protocol.

•4mo ago

BrainsWay Announces Minority-Stake Investment in Hopemark Health

BrainsWay announced a strategic equity investment in Hopemark Health, a mental health clinic network in the Chicago area, to expand access to its Deep TMS technology. The company will invest $1.5 million initially, with an option for an additional $1.5 million in milestone-based payments, for a minority stake in the form of a preferred, annually compounding security. CEO Hadar Levy stated the move supports BrainsWay’s strategy to partner with growth-oriented clinical platforms while remaining focused on its core technology advancement.

•5mo ago